公开(公告)号：NZ551508A

公开(公告)日：2010-10-29

申请号：NZ55150805

申请日：2005-04-29

Applicant: ABBOTT LAB

Inventor： LINK JAMES T ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J ,  WODKA DARIUSZ ,  PATEL JYOTI R ,  SHUAI QI

IPC: C07D207/02 ,  C07C237/04 ,  C07C237/24 ,  C07D209/08 ,  C07D213/06 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: Disclosed is a compound according to formula (I) wherein A1 is alkyl-NH-alkyl, alkylcarbonyl, alkylsulfonyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, arylcarbonyl, arylsulfonyl, heterocyclecarbonyl, heterocyclesulfonyl, arylalkyl, aryloxyalkyl, carboxyalkyl, carboxycycloalkyl, haloalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, -NR7-[C(R8R9)]n-C(O)-R10, -O-[C(R11R12)]p-C(O)-R13, -N(R15R16), -CO2R17, -C(O)-N(R18R19), -CR20R21)-OR22, or -C(R23R24)-N(R25R26); and wherein the rest of the substituents are disclosed within the specification. Also disclosed is the use of a compound of formula (I) in the manufacture of a medicament for treating a disorder associated with the inhibition of 11-beta-hydroxysteroiddehydrogenase type 1 enzyme selected from Cushing's syndrome, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, hypertension, atherosclerosis, glaucoma, and osteoporosis.

公开(公告)号：ZA200705468B

公开(公告)日：2010-03-31

申请号：ZA200705468

申请日：2007-07-04

Applicant: ABBOTT LAB

Inventor： ROHDE JEFFREY J ,  LINK JAMES T ,  DINGES JURGEN ,  YONG HONG ,  KURUKULASURIYA RAVI ,  SHUAI QI ,  PATEL JYOTI R ,  SORENSEN BRYAN K ,  YEH VINCE S

IPC: A61K20100101 ,  A61P20100101 ,  C07C20100101 ,  C07D20100101

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：BRPI0606228A2

公开(公告)日：2009-06-09

申请号：BRPI0606228

申请日：2006-01-05

Applicant: ABBOTT LAB

Inventor： ROHDE JEFFREY J ,  LINK JAMES T ,  PATEL JYOTI R ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  YONG HONG ,  SHUAI QI

IPC: C07C233/63 ,  A61K31/165 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61K31/4409 ,  A61P3/04 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：HK1117138A1

公开(公告)日：2009-01-09

申请号：HK08104526

申请日：2008-04-23

Applicant: ABBOTT LAB

Inventor： PATEL JYOTI R ,  SHUAI QI ,  LINK JAMES T ,  ROHDE JEFFREY J ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

IPC: A61K20060101 ,  A61P20060101 ,  C07C20060101 ,  C07D20060101

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：MX2007008239A

公开(公告)日：2007-08-17

申请号：MX2007008239

申请日：2006-01-05

Applicant: ABBOTT LAB

Inventor： YONG HONG ,  LINK JAMES T ,  ROHDE JEFFREY J ,  PATEL JYOTI R ,  SHUAI QI ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  YEH VINCE S ,  KURUKULASURIYA RAVI

IPC: C07C233/63 ,  A61K31/165 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61K31/4409 ,  A61P3/04 ,  A61P3/10 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: La presente invencion se refiere a compuestos que son inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa Tipo I. La presente invencion ademas se refiere al uso de inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa Tipo I para el tratamiento de la diabetes tipo 2 no-insulina dependiente, resistencia a la insulina, obesidad, trastornos de lipidos, sindrome metabolico y otras enfermedades y condiciones que son mediadas por la accion excesiva de glucocorticoides.

公开(公告)号：UY28228A2

公开(公告)日：2004-04-30

申请号：UY28228

申请日：2004-03-11

Applicant: ABBOTT LAB

Inventor： GELDEM THOMAS W VON ,  KYM PHILIP R ,  JACOBSON PEER B ,  LINK JAMES T ,  LAI CHUNQIU ,  BISHOP RICHARD D ,  TU NOAH ,  RICHARDS STEVEN J ,  GATES BRADLEY D

IPC: A61P3/10 ,  C07C49/527 ,  C07C49/657

Abstract: Nuevos compuestos que son antagonistas selectivos del receptor glucocorticoides en el hígado, métodos para preparar dichos compuestos métodos para usar tales compuestos en la regulación del metabolismo especialmente para bajar los niveles de glucosa sérica los niveles de insulina, los niveles de lípidos, y/o reducir el peso corporal